New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies
Autor: | William R. Freeman, Kristyn Huffman, Lingyun Cheng, Sang Woong Moon, Yaoyao Sun, Michael J. Sailor, David Warther |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Vascular Endothelial Growth Factor A intravitreal drug delivery Proliferative vitreoretinopathy Pharmaceutical Science Neurodegenerative Eye chemistry.chemical_compound Macular Degeneration 0302 clinical medicine Drug Delivery Systems oct matrigel Pharmacology & Pharmacy Fluorescein Angiography Tomography vegf education.field_of_study Neovascularization Pathologic General Medicine Diabetic retinopathy Pharmacology and Pharmaceutical Sciences VEGF 3. Good health Vascular endothelial growth factor Drug Combinations Choroidal neovascularization porous silicon Intravitreal Injections Proteoglycans Collagen Rabbits medicine.symptom subretinal injection Tomography Optical Coherence medicine.drug Research Article medicine.medical_specialty Population dexamethasone rabbit model of pvr Intravitreal drug delivery 03 medical and health sciences Matrigel Ophthalmology Proliferative medicine Animals education Macular edema Eye Disease and Disorders of Vision Dexamethasone Neovascularization Pathologic fundus fluorescein angiography business.industry Vitreoretinopathy Proliferative lcsh:RM1-950 Neurosciences rabbit model of PVR medicine.disease eye diseases Vitreous Body 030104 developmental biology lcsh:Therapeutics. Pharmacology chemistry OCT Optical Coherence Delayed-Action Preparations 030221 ophthalmology & optometry Laminin sense organs business Vitreoretinopathy |
Zdroj: | Drug Delivery, Vol 25, Iss 1, Pp 600-610 (2018) Drug Delivery Drug delivery, vol 25, iss 1 |
ISSN: | 1521-0464 1071-7544 |
Popis: | Blinding retinal diseases become more epidemic as the population ages. These diseases, such as diabetic retinopathy and macular edema, are of chronic nature and require protracted drug presence at the disease site. A sustained intravitreal porous silicon delivery system with dexamethasone (pSiO2-COO-DEX) was evaluated in a new rabbit model of proliferative vitreoretinopathy (PVR) in a real treatment design. In contrast to the pretreatment design model, pSiO2-COO-DEX was intravitreally injected into the eyes with active inflammation. Subretinal injection of vascular endothelial growth factor (VEGF) and Matrigel induced a late-onset vitreoretinal inflammation that gradually developed into PVR. This method mimics the human disease better than PVR induced by either intravitreal cell injection or trauma. The pSiO2-COO-DEX intervened eyes had minimal PVR, while balanced saline solution or free dexamethasone intervened eyes had significantly more PVR formation. In addition, adding VEGF to the Matrigel for subretinal injection induced greater inflammation and retinal neovascularization in comparison to only Matrigel injected under the medullary ray. Clinical and pathological examinations, including fundus fluorescein angiography and optical coherence tomography, confirmed these changes. In the current study, neither subretinal injection of Matrigel or subretinal injection of VEGF and Matrigel induced choroidal neovascularization. However, the current PVR model demonstrates a chronic course with moderate severity, which may be useful for drug screening studies. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |